🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesMetabolic syndrome reversal criteria — what worked for you? Page 2

Metabolic syndrome reversal criteria — what worked for you?

anna.melb_AU Wed, Feb 7, 2024 at 7:40 PM 61 replies 3,475 viewsPage 2 of 13
InsuranceTom
Senior Member
1,345
7,890
Mar 2024
Connecticut
Feb 7, 2024 at 9:04 PM#6
DebRD_ATL said:
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 35% to 19%.

PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

After 12 months: periods became regular for the first time in ever, testosterone levels normalized, acne cleared significantly, and — unexpectedly — my hormonal symptoms have almost completely resolved.

GLP-1 agonists address the insulin resistance at the root of PCOS. For PCOS patients, this isn't "just" a weight loss drug — it's treating our underlying metabolic dysfunction.

9 4lisa_labSD, adam_van, Dr.SurgeonPGH and 6 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Feb 7, 2024 at 9:37 PM#7
anna.melb_AU said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

My labs after 3 months on glycaemic control: A1C 5.6%, fasting glucose 91 mg/dL, fasting insulin 4 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.7% and fasting glucose was 116 mg/dL. The improvement has been dramatic and consistent.

8 3HPLC_Greg, LibrarianMeg, bri_stats and 5 others
Reply Quote Save Share Report
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Feb 7, 2024 at 10:10 PM#8
InsuranceTom said:
PCOS success story with glycaemic control: as someone with polycystic ovary syndrome, this medication has been transformative beyond weight loss.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1271059183
Insulin (fasting)2313116
HOMA-IR5.53.81.91.1
Uric Acid8.56.75.84.8

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 5.5 to near 1.0 is a metabolic transformation.

7 2MarkLI_maint, Dr.PeteFamMed, claudia_zurich and 4 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
FitDadDave
Member
534
2,678
Jul 2024
Minneapolis, MN
Feb 7, 2024 at 10:43 PM#9

Following on from SallyK_inj — and this may be the naive question:

Was that from a primary source or from a summary of one?

Last edited: Feb 8, 2024 at 1:43 AM
6 1wendy_avl, jason_paloalto, Dr.LeslieOBGYN and 3 others
Reply Quote Save Share Report
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
Feb 8, 2024 at 1:19 AM#10
GenomicsKate said:
Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone: Test Baseline Month 3 Month 6 Month 12…

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 5.5 (insulin resistant) → Current = 1.3 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

10 10Dr.LipidDallas, alex_tucson, kevin_tulsa and 7 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register